Targeted therapies have really come to the forefront of cancer treatment. The purpose of this webinar is to discuss the role of FGFR testing which has received a lot of attention recently due to its importance in the role of advanced bladder cancer management. In the fall of 2019, clearance was granted by the FDA and Health Canada for Janssen’s Balversa/ erdafitinib, which is the first approved FGFR kinase inhibitor in eligible bladder cancer patients.

In the first half of the talk, Dr. Alan Spatz, Chief of the Division of Molecular Genetics at the Jewish General Hospital in Montreal, will cover the epidemiology and clinical features of bladder cancer, and broadly touch on the management of localized and advanced disease, as well as some of the prognostic features that determine management.

In the second half, Dr. Shamini Selvarajah, a clinical laboratory scientist in the Clinical Genetics Laboratory at the University Health Network, will discuss FGFR alterations in bladder cancer as well as review the testing process, sample requirements and reporting for the testing which will be carried out by labs at the UHN and the Jewish General Hospital. These are the two sites that are being funded by Janssen to perform FGFR testing for a select group of bladder cancer patients across Canada.

свернуть